News overview

20191104 Get the patient into the lab Card Image
4 November 2019
Highlights of Oncode’s Glioblastoma Workshop
On October 16th 2019, Oncode held the second in the series of clinical workshops with the aim to strengthen the link between fundamental and clinical research.
Vesnade Jong
20191101 TEIPP targeting immunotherapy project funded by Oncode Institute Card Image
1 November 2019
TEIPP-targeting immunotherapy project funded by Oncode Institute
Oncode clinical Proof of concept Programme will fund the “TEIPP-targeting immunotherapy” project from Sjoerd van der Burg
20191028 Inaugural lecture Karin de Visser Card Image
28 October 2019
Inaugural lecture Karin de Visser
On Friday, 15 November 2019, Oncode Investigator Karin de Visser (NKI) will give her inaugural lecture (in Dutch) on the topic of Tumor Biology and Immunology with the title: 'The immune system: a double-edged sword that needs direction'. This event will take place at16.00 at the University of Leiden, (Academiegebouw, Rapenburg 73, 2311 GJ Leiden) and will be followed by a reception. The Oncode community is invited to be present at this ceremony.
Vesnade Jong
Anne Rios 2
25 October 2019
Anne Rios receives the St. Baldrick’s Robert J. Arceci Innovation Award
Oncode Investigator Anne Rios of the Princess Máxima Center received the St. Baldrick’s Robert J. Arceci Innovation Award at the annual SIOP congress in Lyon, France. This is the first time the award has gone to the Netherlands.
Coverbeeld Q3
15 October 2019
Oncode Quarterly Magazine - October 2019
Welcome to the second edition of our quarterly magazine. Are you curious what kept us busy the past few months? In this edition you can read interviews with Jannie Borst, Andrea van Elsas, Ruben van Boxtel and Rebekka Schneider. And there's much more!
Vesnade Jong
11 October 2019
Geert Kops receives ERC Synergy Grant
Oncode's Scientific Director Geert Kops (Hubrecht Institute) has received a European Research Council (ERC) Synergy Grant to investigate the causes and effects of chromosomal aberrations in cancer, together with Iva Tolic (Ruder Boskovic Institute), Angelika Amon (Massachusetts Institute of Technology) and Nenad Pavin (University of Zagreb). Together they receive 10 million euros for their interdisciplinary effort that combines cell biology, bio(physics) and genetics.
Tumor Growth Theme
11 October 2019
The mutational impact of fluoropyrimidines
In their latest paper in Nature Communications, Oncode Investigator Edwin Cuppen and Arne van Hoeck (UMC Utrecht), together with colleagues, assess the mutational impact of fluoropyrimidines.
10 October 2019
ESMO 2019: what have we learnt?
While the autumn started showing itself in some parts of Europe, the sun was shining in the city of Gaudi which was home to more than 28,000 attendees for the ESMO 2019 annual congress. For one week, Barcelona was flooded with top-quality science and ambitious visions that will shape the future of cancer therapies.
Leila Akkari 2
3 October 2019
'One-two punch' method published in Nature
The labs from Oncode Investigators René Bernards and Leila Akkari (NKI) have published the results of important research in Nature. Many combinations of cancer medicines could theoretically work very well together, but in practice these combinations are too toxic for the body to withstand. The researchers devised a possible alternative: the 'one-two punch', named after the effective combination of two quick successive punches in boxing.
Drug Combinations Theme
3 October 2019
DRUP study in Nature
In 2016, the Drug Rediscovery Protocol was launched in the Netherlands. This is a unique and innovative pan-cancer clinical trial that seeks to expand the use of EMA and/or FDA-approved targeted therapies beyond their approved indications. In a Nature paper, published 30 September, the research team now takes stock of the progress of DRUP over the first three years.
27 September 2019
NKI starts EM facility for the Oncode community
Oncode’s Equipment and Infrastructure programme aims to support the research community by enabling joint equipment- and infrastructure-based projects between different institutes.
Vesnade Jong
Oncode Icons Square 14
27 September 2019
A cost-effective treatment strategy for metastatic colorectal carcinoma patients
The sustainability of the healthcare system is under extreme pressure, given the increasing costs associated with research, drug development, treatment and hospital care. Through support of its Investigators’ research and development activities, Oncode is working to advance new and innovative therapies to patients.
Vesnade Jong